Le Lézard
Classified in: Health
Subjects: NPT, SVY

Poorer Socioeconomic Status Predicts Lower Survival in Patients with Anal Cancer


NEW YORK, March 12, 2018 /PRNewswire-USNewswire/ -- If you are from a lower income area, your chances of surviving anal cancer are significantly reduced, according to a new study led by investigators at NYU Langone Health's Perlmutter Cancer Center, and publishing online March 12, 2018 in Cancer.

NYU Langone Health logo (PRNewsFoto/NYU Langone Medical Center)

Among the first of its kind, the study shows that both overall survival -- and cancer specific survival -- can be predicted by median household income (MHI) after controlling for additional factors like age, sex, race, and stage of cancer. Investigators found chance of death increased by about 30 percent for those living in areas of poverty.

"Living in a low-income area shouldn't dictate your outcome with cancer and, based on this research, we're seeing that it does," says Daniel Becker, MD, clinical assistant professor in the Department of Medicine and Division of Hematology and Medical Oncology at Perlmutter Cancer Center. "The benefit of this study is that we're identifying higher-risk populations that need additional resources to improve outcomes."

As a relatively rare, but highly treatable disease, squamous cell carcinoma of the anus (SCAA) has been rising in incidence and currently accounts for more than 8,200 cases annually in the United States. This increasing incidence is potentially due to changing trends in sexual behavior and other risk factors like human papilloma virus and smoking.

How the Study Was Conducted

MHI had the strongest association with both overall survival and, specifically, survival from anal cancer. Other secondary predictors of lower survival from anal cancer include gender (men are more vulnerable), older age, African-American race, unmarried status, and, like in most cancers, when it is diagnosed.

The data on SCAA for this study, collected from the Surveillance Epidemiology and End Results Cancer Registry between 2004 and 2013, included a total of 9,550 study participants. MHI, age, sex, race, marital status, stage and grade of cancer, year of diagnosis and radiation-treatment status were recorded. MHI was broken into five distinct wage-earning categories for analysis?less than $46, 840; $46,840-$56,369; $56,270-$60,709; $60,710-$70,819; and more than $70,820. Historically, area-based poverty has been linked to cancer mortality in other tumor types as well -- and this study underscores those findings.

"We've made tremendous progress in other areas of cancer to improve screening, treatment and outcomes," says Becker. "Education and improvements are possible?we can start by going into these communities to make sure that all patients, regardless of their economic status, have the access to cancer care that they need."

Besides Becker, other NYU Langone and NYU School of Medicine researchers involved in this research study were co-investigators Daniel Lin, MD; Heather Gold, PhD; Lawrence Leichman, MD; and Scott Sherman, MD.

Media Inquiries:
Jamie Liptack
212-404-4279
[email protected] 

SOURCE NYU Langone Health


These press releases may also interest you

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...



News published on and distributed by: